#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

What It Covers

Cardiologist and lipidologist Michael Davidson joins Peter Attia to examine why LDL should be treated as a causal driver of disease from early adulthood, the history and science behind CETP inhibition, obicetrapib's clinical trial data across cardiovascular and metabolic outcomes, and emerging evidence that raising HDL via CETP inhibition may reduce Alzheimer's disease risk in APOE4 carriers.

Key Questions Answered

• •Primordial Prevention & the 8-Gram Rule: Lifetime LDL exposure, not short-term risk scores, determines atherosclerosis development. The "8-gram rule" frames this concretely: 200 mg/dL LDL over 40 years equals the same cumulative cholesterol burden as 80 mg/dL over 100 years. Keeping LDL below 80 mg/dL throughout life appears sufficient to prevent heart disease. Starting lipid-lowering therapy in one's 30s, before plaque forms, is far more effective than reversing established disease later.
• •LDL Causality Is Mechanism-Independent: Every primary prevention trial, secondary prevention trial, and Mendelian randomization study, when plotted together, shows the same linear relationship: each 38.8 mg/dL (1 mmol/L) reduction in LDL produces approximately a 22% relative risk reduction in cardiovascular events. This holds regardless of whether LDL is lowered by statins, ezetimibe, PCSK9 inhibitors, or CETP inhibition, which eliminates the pleiotropic effects argument and confirms LDL itself as the causal driver.
• •Obicetrapib's Lipid Profile vs. Prior CETP Inhibitors: At just 10 mg orally, obicetrapib lowers LDL cholesterol by 45–50% as monotherapy, raises HDL by 150%, reduces LDL particle number by wiping out small dense particles by approximately 90%, and lowers Lp(a) by roughly 50%—exceeding PCSK9 inhibitors on Lp(a) reduction. Prior CETP inhibitors required 100+ mg doses for 10–20% LDL lowering. The potency difference explains why earlier drugs failed to demonstrate cardiovascular benefit within two-year trial windows.
• •Why Earlier CETP Trials Failed: Torcetrapib raised aldosterone via off-target adrenal effects unrelated to CETP inhibition, confirmed because blood pressure rose in rats that lack CETP entirely. Dalcetrapib was too weak. Evacetrapib was stopped for futility at two years—likely prematurely, since ezetimibe's cardiovascular benefit in a comparable acute coronary syndrome trial only became statistically significant after two years. The Merck anacetrapib trial (30,000 patients, four years) ultimately confirmed CETP inhibition does reduce cardiovascular events proportional to LDL lowering.
• •Obicetrapib as a Statin Companion Drug: Statins slightly raise Lp(a), modestly raise diabetes risk, and do not meaningfully reduce small LDL particles. Obicetrapib addresses all three liabilities: Broadway trial data show a 21% directional reduction in major adverse cardiac events at one year, reduced diabetes risk, ~50% Lp(a) lowering, and 90% reduction in small particles. Combined with ezetimibe in a single pill, the LDL lowering reaches PCSK9 inhibitor levels orally, potentially covering 90% of patients' lipid treatment needs after a statin.
• •APOE4 and Obicetrapib's Alzheimer's Signal: APOE4 impairs cholesterol efflux and lipidation in astrocytes, disrupting neuronal nourishment and triggering amyloid and tau accumulation. HDL is the only lipoprotein that crosses the blood-brain barrier via SRB1 receptors in the choroid plexus. In the Broadway trial's pre-specified biomarker analysis, obicetrapib reduced plasma p-tau217 overall, with APOE4 homozygotes showing reductions across all Alzheimer's biomarkers—p-tau217, p-tau181, GFAP, amyloid 42/40 ratio, and neurofilament light—by over 20% versus placebo.
• •Alzheimer's Prevention Requires Earlier Intervention: Pathological changes in amyloid and tau begin approximately 20 years before mild cognitive impairment (MCI) appears. By the time MCI is diagnosed, brain atrophy and neurodegeneration are already established, making reversal unlikely—analogous to treating heart failure with statins, which shows no benefit. Davidson's planned 300-patient study targets APOE4 carriers before MCI onset, using p-tau217 as the primary endpoint, aiming to demonstrate conversion prevention from normal cognition to MCI.